Mechanical recanalization of the culprit artery in acute myocardial infarction using stents
provides in 2003, TIMI 3 flow restoration in more than 90% of patients. However, the
prognosis of this condition remains poor, to a large degree because of microcirculatory
dysfunction that is observed, in near than 20 to 40 % of patients, during or following
primary percutaneous intervention. The lack of ST-segment elevation resolution after
angioplasty with stenting is a marker of microcirculatory dysfunction and is associated with
a poor prognosis. Routine administration with primary stenting of the platelet glycoprotein
IIb/IIIa inhibitor Abciximab in acute myocardial infarction is still a matter of debate with
conflicting results emerging from two major clinical studies ADMIRAL and CADILLAC. However,
evidences are in favour of a benefit of this treatment especially when administrated early
(in a pre-hospital manner) before percutaneous coronary intervention.Our primary purpose is
to investigate the benefit of an early (i.e. pre-hospital) vs. a conventional (i.e.
per-angiography) administration of Abciximab on ST-segment elevation regression at one hour
after primary percutaneous angioplasty.
Phase:
Phase 3
Details
Lead Sponsor:
University Hospital, Strasbourg, France
Collaborator:
Eli Lilly and Company
Treatments:
Abciximab Antibodies, Monoclonal Immunoglobulin Fab Fragments